EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Temporal trends in the cost and use of first‐line treatments for infantile epileptic spasms syndrome

Iván Sánchez Fernández iD, Marta Amengual-Gual iD, Cristina Barcia Aguilar iD, Amanda Romeu, Tahir Sheikh, Alcy Torres, Jessica Chao, Rinat Jonas, Marina Gaínza-Lein iD, Chellamani Harini, Laurie Douglass iD

Epilepsia · 2023

DOI: 10.1111/epi.17498 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia, 2023. Verfasst von Iván Sánchez Fernández und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatrics, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Vigabatrin, Spasms, Infantile. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe the temporal trends in the cost and use of adrenocorticotropic hormone (ACTH), oral prednisolone, and vigabatrin, the first‐line treatments for infantile epileptic spasms syndrome (IESS).

Methods

Retrospective observational study using the MarketScan Commercial database from 2006 to 2020. We identified patients with IESS diagnosed between birth and 18 months of age who received at least one of the first‐line treatments within 60 days of diagnosis. Costs were adjusted for inflation using the Gross Domestic Product Implicit Price Deflator.

Results

A total of 1131 patients received at least one first‐line treatment (median [p 25 –p 75 ] age: 6.3 [4.5–8.3] months, 55% male), of whom 592 patients received ACTH, 363 patients received oral prednisolone, and 355 patients received vigabatrin. After adjusting for inflation, the median average wholesale price of a 14‐day course of treatment increased for ACTH from $3718 in 2006 to $100 457 in 2020, ~2700% (by a factor of 27), whereas it decreased for oral prednisolone from $169 in 2006 to $89 in 2020, ~50% (by a factor of 0.5), and increased for vigabatrin from $1206 in 2009 (first year with data on vigabatrin used for IESS) to $4102 in 2020, ~340% (by a factor of 3.4). During the first 60 days after diagnosis, inpatient admission days and costs where higher for ACTH than for oral prednisolone and vigabatrin—5.0 (3.0–8.3) days vs 2.0 (0.0–5.0) days vs 2.0 (0.0–6.0) days, p < .0001; and $32 828 ($14 711–$67 216) vs $16 227 ($0–$35 829) vs $17 844 ($0–$47 642), p < .0001. ACTH use decreased from representing 78% of first‐line treatments in 2006 to 18% in 2020 ( p < .0001). Sensitivity analyses confirmed the robustness of the results. Significance The gap between the cost of ACTH and the cost of oral prednisolone or vigabatrin has widened markedly from 2006 to 2020, whereas the relative proportion of ACTH use has decreased.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VigabatrinSpasms, InfantileHumansMaleInfantChildInfant, NewbornFemaleAnticonvulsantsAdrenocorticotropic HormonePrednisoloneSyndromeSpasmTreatment Outcome

Stichwörter der Autor:innen

drug costeconomic evaluation of health policyhealth care costinfantile spasmsoutcomes researchtreatment

Substanzen

VigabatrinAnticonvulsantsAdrenocorticotropic HormonePrednisolone

Autor:innen und Institutionen

  • Division of Pediatric Neurology, Department of Pediatrics, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Pediatric Neurology Unit, Department of Pediatrics, Hospital Universitari Son Llàtzer, Universitat de les Illes Balears, Palma, Spain.
  • Pediatric Neurology Unit, Department of Pediatrics, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain.
  • Instituto de Pediatría, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile.
  • Servicio de Neuropsiquiatría Infantil, Hospital Clínico San Borja Arriarán, Universidad de Chile, Santiago, Chile.
  • Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Iván Sánchez Fernández, Marta Amengual-Gual, Cristina Barcia Aguilar, Marina Gaínza-Lein, Laurie Douglass

Zitieren

APA

Sánchez Fernández, I., Amengual-Gual, M., Barcia Aguilar, C., Romeu, A., Sheikh, T., Torres, A., Chao, J., Jonas, R., Gaínza-Lein, M., Harini, C., & Douglass, L. (2023). Temporal trends in the cost and use of first‐line treatments for infantile epileptic spasms syndrome. Epilepsia. https://doi.org/10.1111/epi.17498

Vancouver

Sánchez Fernández I, Amengual-Gual M, Barcia Aguilar C, Romeu A, Sheikh T, Torres A, et al. Temporal trends in the cost and use of first‐line treatments for infantile epileptic spasms syndrome. Epilepsia. 2023. doi:10.1111/epi.17498

BibTeX
@article{SnchezFernndez2023,
  author = {Sánchez Fernández, Iván and Amengual-Gual, Marta and Barcia Aguilar, Cristina and Romeu, Amanda and Sheikh, Tahir and Torres, Alcy and Chao, Jessica and Jonas, Rinat and Gaínza-Lein, Marina and Harini, Chellamani and Douglass, Laurie},
  title = {Temporal trends in the cost and use of first‐line treatments for infantile epileptic spasms syndrome},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17498}
}
Kostenlos starten →